{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:59:33Z","timestamp":1792511973325,"version":"4.5.0"},"reference-count":113,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T00:00:00Z","timestamp":1706140800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Pseudomonas aeruginosa (P. aeruginosa) with multi-drug resistance (MDR) is a major cause of serious healthcare-associated infections, leading to high morbidity and mortality. This opportunistic pathogen is responsible for various infectious diseases, such as those seen in cystic fibrosis, ventilator-associated pneumonia, urinary tract infection, otitis externa, and burn and wound injuries. Due to its relatively large genome, P. aeruginosa has great diversity and can use various molecular mechanisms for antimicrobial resistance. For example, outer membrane permeability can contribute to antimicrobial resistance and is determined by lipopolysaccharide (LPS) and porin proteins. Recent findings on the regulatory interaction between peptidoglycan and LPS synthesis provide additional clues against pathogenic P. aeruginosa. This review focuses on recent advances in antimicrobial agents and inhibitors targeting LPS and porin proteins. In addition, we explore current and emerging treatment strategies for MDR P. aeruginosa, including phages, vaccines, nanoparticles, and their combinatorial therapies. Novel strategies and their corresponding therapeutic agents are urgently needed for combating MDR pathogens.<\/jats:p>","DOI":"10.3390\/antibiotics13020119","type":"journal-article","created":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T06:54:12Z","timestamp":1706165652000},"page":"119","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Advances in Development of Novel Therapeutic Strategies against Multi-Drug Resistant Pseudomonas aeruginosa"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4360-5320","authenticated-orcid":false,"given":"Changhong","family":"Yin","sequence":"first","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Brody School of Medicine, East Carolina University, Greenville, NC 27834, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md Zahidul","family":"Alam","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Brody School of Medicine, East Carolina University, Greenville, NC 27834, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7677-4868","authenticated-orcid":false,"given":"John T.","family":"Fallon","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Brody School of Medicine, East Carolina University, Greenville, NC 27834, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weihua","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Brody School of Medicine, East Carolina University, Greenville, NC 27834, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,1,25]]},"reference":[{"key":"ref_1","unstructured":"Antimicrobial Resistance Collaborators (2022). Global burden of bacterial antimicrobial resistance in 2019: A systematic analysis. Lancet, 399, 629\u2013655."},{"key":"ref_2","unstructured":"(2024, January 23). Multidrug-Resistant Pseudomonas aeruginosa, Available online: https:\/\/arpsp.cdc.gov\/profile\/antibiotic-resistance\/mdr-pseudomonas-aeruginosa."},{"key":"ref_3","first-page":"1","article-title":"Antimicrobial-resistant pathogens associated with adult healthcare-associated infections: Summary of data reported to the National Healthcare Safety Network, 2015\u20132017","volume":"41","author":"Abner","year":"2020","journal-title":"Infect. Control Hosp. Epidemiol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/S1473-3099(17)30753-3","article-title":"Discovery, research, and development of new antibiotics: The WHO priority list of antibiotic-resistant bacteria and tuberculosis","volume":"18","author":"Tacconelli","year":"2018","journal-title":"Lancet Infect. Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.jinf.2020.05.046","article-title":"Co-infections in people with COVID-19: A systematic review and meta-analysis","volume":"81","author":"Lansbury","year":"2020","journal-title":"J. Infect."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Bongiovanni, M., and Barda, B. (2023). Pseudomonas aeruginosa Bloodstream Infections in SARS-CoV-2 Infected Patients: A Systematic Review. J. Clin. Med., 12.","DOI":"10.3390\/jcm12062252"},{"key":"ref_7","unstructured":"(2024, January 23). Outbreak of Extensively Drug-Resistant Pseudomonas aeruginosa Associated with Artificial Tears, Available online: https:\/\/www.cdc.gov\/hai\/outbreaks\/crap-artificial-tears.html."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/s41579-022-00820-y","article-title":"Molecular mechanisms of antibiotic resistance revisited","volume":"21","author":"Darby","year":"2023","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Munita, J.M., and Arias, C.A. (2016). Mechanisms of Antibiotic Resistance. Microbiol. Spectr., 4.","DOI":"10.1128\/microbiolspec.VMBF-0016-2015"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/s41392-022-01056-1","article-title":"Pseudomonas aeruginosa: Pathogenesis, virulence factors, antibiotic resistance, interaction with host, technology advances and emerging therapeutics","volume":"7","author":"Qin","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1093\/infdis\/171.5.1250","article-title":"Lipopolysaccharide toxicity-regulating proteins in bacteremia","volume":"171","author":"Froon","year":"1995","journal-title":"J. Infect. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Huszczynski, S.M., Lam, J.S., and Khursigara, C.M. (2019). The Role of Pseudomonas aeruginosa Lipopolysaccharide in Bacterial Pathogenesis and Physiology. Pathogens, 9.","DOI":"10.3390\/pathogens9010006"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2174\/138920108783497668","article-title":"Mechanism and inhibition of LpxC: An essential zinc-dependent deacetylase of bacterial lipid A synthesis","volume":"9","author":"Barb","year":"2008","journal-title":"Curr. Pharm. Biotechnol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1128\/AAC.05417-11","article-title":"Mechanisms decreasing in vitro susceptibility to the LpxC inhibitor CHIR-090 in the gram-negative pathogen Pseudomonas aeruginosa","volume":"56","author":"Caughlan","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3112","DOI":"10.1021\/jm010579r","article-title":"Potent, novel in vitro inhibitors of the Pseudomonas aeruginosa deacetylase LpxC","volume":"45","author":"Kline","year":"2002","journal-title":"J. Med. Chem."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1128\/AAC.00140-06","article-title":"Molecular validation of LpxC as an antibacterial drug target in Pseudomonas aeruginosa","volume":"50","author":"Mdluli","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1080\/13543776.2017.1360282","article-title":"LpxC inhibitors: A patent review (2010\u20132016)","volume":"27","author":"Kalinin","year":"2017","journal-title":"Expert Opin. Ther. Pat."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"16574","DOI":"10.1021\/bi0518186","article-title":"A slow, tight-binding inhibitor of the zinc-dependent deacetylase LpxC of lipid A biosynthesis with antibiotic activity comparable to ciprofloxacin","volume":"44","author":"McClerren","year":"2005","journal-title":"Biochemistry"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e00977-19","DOI":"10.1128\/AAC.00977-19","article-title":"Potent LpxC Inhibitors with In Vitro Activity against Multidrug-Resistant Pseudomonas aeruginosa","volume":"63","author":"Krause","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.2174\/1568026616666160413135835","article-title":"Insights into the Zinc-Dependent Deacetylase LpxC: Biochemical Properties and Inhibitor Design","volume":"16","author":"Kalinin","year":"2016","journal-title":"Curr. Top. Med. Chem."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e01551-14","DOI":"10.1128\/mBio.01551-14","article-title":"LpxC inhibitors as new antibacterial agents and tools for studying regulation of lipid A biosynthesis in Gram-negative pathogens","volume":"5","author":"Tomaras","year":"2014","journal-title":"mBio"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Alkatheri, A.H., Yap, P.S.-X., Abushelaibi, A., Lai, K.-S., Cheng, W.-H., and Lim, S.-H.E. (2023). Microbial Genomics: Innovative Targets and Mechanisms. Antibiotics, 12.","DOI":"10.3390\/antibiotics12020190"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"a025304","DOI":"10.1101\/cshperspect.a025304","article-title":"Antibacterial Drug Discovery Targeting the Lipopolysaccharide Biosynthetic Enzyme LpxC","volume":"6","author":"Erwin","year":"2016","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/cmdc.201900287","article-title":"Optimization of LpxC Inhibitors for Antibacterial Activity and Cardiovascular Safety","volume":"14","author":"Cohen","year":"2019","journal-title":"ChemMedChem"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"eadf5668","DOI":"10.1126\/scitranslmed.adf5668","article-title":"Preclinical safety and efficacy characterization of an LpxC inhibitor against Gram-negative pathogens","volume":"15","author":"Zhao","year":"2023","journal-title":"Sci. Transl. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1177\/1753425909106436","article-title":"Review: Lipopolysaccharide biosynthesis in Pseudomonas aeruginosa","volume":"15","author":"King","year":"2009","journal-title":"Innate Immun."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1038\/s41586-023-05750-0","article-title":"Coordination of bacterial cell wall and outer membrane biosynthesis","volume":"615","author":"Hummels","year":"2023","journal-title":"Nature"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"3757","DOI":"10.1074\/jbc.M411325200","article-title":"Evidence that the fosfomycin target Cys115 in UDP-N-acetylglucosamine enolpyruvyl transferase (MurA) is essential for product release","volume":"280","author":"Eschenburg","year":"2005","journal-title":"J. Biol. Chem."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1086\/429323","article-title":"Colistin: The revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections","volume":"40","author":"Falagas","year":"2005","journal-title":"Clin. Infect. Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S1473-3099(15)00424-7","article-title":"Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: A microbiological and molecular biological study","volume":"16","author":"Liu","year":"2016","journal-title":"Lancet Infect. Dis."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.ijantimicag.2016.06.023","article-title":"Molecular mechanisms of polymyxin resistance: Knowns and unknowns","volume":"48","author":"Baron","year":"2016","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1124\/pharmrev.120.000020","article-title":"Rescuing the Last-Line Polymyxins: Achievements and Challenges","volume":"73","author":"Nang","year":"2021","journal-title":"Pharmacol. Rev."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.ijmm.2016.03.001","article-title":"Structure and function: Lipid A modifications in commensals and pathogens","volume":"306","author":"Steimle","year":"2016","journal-title":"Int. J. Med. Microbiol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/nrmicro3047","article-title":"Fortifying the barrier: The impact of lipid A remodelling on bacterial pathogenesis","volume":"11","author":"Needham","year":"2013","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e01820-17","DOI":"10.1128\/AAC.01820-17","article-title":"Aminoarabinosylation of Lipid A is Critical for the Development of Colistin Resistance in Pseudomonas aeruginosa","volume":"62","author":"Imperi","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Cervoni, M., Sposato, D., Sciuto, A.L., and Imperi, F. (2023). Regulatory Landscape of the Pseudomonas aeruginosa Phosphoethanolamine Transferase Gene eptA in the Context of Colistin Resistance. Antibiotics, 12.","DOI":"10.3390\/antibiotics12020200"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"10891","DOI":"10.1021\/acs.joc.0c01459","article-title":"ent-Beyerane Diterpenes as a Key Platform for the Development of ArnT-Mediated Colistin Resistance Inhibitors","volume":"85","author":"Quaglio","year":"2020","journal-title":"J. Org. Chem."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e01142-18","DOI":"10.1128\/AAC.01142-18","article-title":"Disrupting Gram-Negative Bacterial Outer Membrane Biosynthesis through Inhibition of the Lipopolysaccharide Transporter MsbA","volume":"62","author":"Alexander","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"17981","DOI":"10.1074\/jbc.R117.802512","article-title":"The lipopolysaccharide transport (Lpt) machinery: A nonconventional transporter for lipopolysaccharide assembly at the outer membrane of Gram-negative bacteria","volume":"292","author":"Sperandeo","year":"2017","journal-title":"J. Biol. Chem."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/s41586-018-0083-5","article-title":"Structural basis for dual-mode inhibition of the ABC transporter MsbA","volume":"557","author":"Ho","year":"2018","journal-title":"Nature"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"6834","DOI":"10.1073\/pnas.1804670115","article-title":"Cell-based screen for discovering lipopolysaccharide biogenesis inhibitors","volume":"115","author":"Zhang","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Pei, S., Lai, L., Sun, W., Lu, Z., Hao, J., Liu, Y., Wu, W., Guan, S., and Su, X. (2023). Discovery of novel tetrahydrobenzothiophene derivatives as MSBA inhibitors for antimicrobial agents. Bioorg Chem., 142.","DOI":"10.1016\/j.bioorg.2023.106932"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1039\/D2MD00373B","article-title":"Design, synthesis and antibacterial evaluation of a novel class of tetrahydrobenzothiophene derivatives","volume":"14","author":"Lai","year":"2023","journal-title":"RSC Med. Chem."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Hulen, C., Racine, P.J., Feuilloley, M., Elomri, A., and Lomri, N.E. (2022). Effects of Verapamil and Two Bisbenzylisoquinolines, Curine and Guattegaumerine Extracted from Isolona hexaloba, on the Inhibition of ABC Transporters from Pseudomonas aeruginosa. Antibiotics, 11.","DOI":"10.3390\/antibiotics11050700"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/s41586-019-1665-6","article-title":"Chimeric peptidomimetic antibiotics against Gram-negative bacteria","volume":"576","author":"Luther","year":"2019","journal-title":"Nature"},{"key":"ref_46","unstructured":"(2014, January 23). Temporarily Halt Enrollment for the Pivotal Phase III Trials PRISM-MDR and PRISM-UDR Evaluating Murepavadin in Patients with Nosocomial Pneumonia. Available online: https:\/\/www.swissbiotech.org\/listing\/polyphor-temporarily-halts-phase-iii-studyor-the-treatment-of-patients-with-nosocomial-pneumonia\/."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"e65836","DOI":"10.7554\/eLife.65836","article-title":"Colistin kills bacteria by targeting lipopolysaccharide in the cytoplasmic membrane","volume":"10","author":"Sabnis","year":"2021","journal-title":"eLife"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Wei, X., Gao, J., Xu, C., Pan, X., Jin, Y., Bai, F., Cheng, Z., Lamont, L., Pletzer, D., and Wu, W. (2023). Murepavadin induces envelope stress response and enhances the killing efficacies of beta-lactam antibiotics by impairing the outer membrane integrity of Pseudomonas aeruginosa. Microbiol. Spectr., 11.","DOI":"10.1128\/spectrum.01257-23"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"5158","DOI":"10.1021\/acs.chemrev.0c01213","article-title":"How to Enter a Bacterium: Bacterial Porins and the Permeation of Antibiotics","volume":"121","author":"Prajapati","year":"2021","journal-title":"Chem. Rev."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1093\/femsre\/fux020","article-title":"Structure, function and regulation of Pseudomonas aeruginosa porins","volume":"41","author":"Chevalier","year":"2017","journal-title":"FEMS Microbiol. Rev."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Maher, C., and Hassan, K.A. (2023). The Gram-negative permeability barrier: Tipping the balance of the in and the out. mBio, 2023.","DOI":"10.1128\/mbio.01205-23"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"10144","DOI":"10.1021\/jm501552x","article-title":"Trends and exceptions of physical properties on antibacterial activity for Gram-positive and Gram-negative pathogens","volume":"57","author":"Brown","year":"2014","journal-title":"J. Med. Chem."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1111\/j.1365-2958.1996.tb02532.x","article-title":"From acids to osmZ: Multiple factors influence synthesis of the OmpF and OmpC porins in Escherichia coli","volume":"20","author":"Pratt","year":"1996","journal-title":"Mol. Microbiol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1128\/jb.152.2.636-642.1982","article-title":"Permeability of Pseudomonas aeruginosa outer membrane to hydrophilic solutes","volume":"152","author":"Yoshimura","year":"1982","journal-title":"J. Bacteriol."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Eren, E., Vijayaraghavan, J., Liu, J., Cheneke, B.R., Touw, D.S., Lepore, B.W., Indic, M., Movileanu, L., and Berg, B.v.D. (2012). Substrate specificity within a family of outer membrane carboxylate channels. PLoS Biol., 10.","DOI":"10.1371\/journal.pbio.1001242"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1146\/annurev.micro.56.012302.160310","article-title":"Function of pseudomonas porins in uptake and efflux","volume":"56","author":"Hancock","year":"2002","journal-title":"Annu. Rev. Microbiol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1021\/acsinfecdis.8b00149","article-title":"Getting Drugs through Small Pores: Exploiting the Porins Pathway in Pseudomonas aeruginosa","volume":"4","author":"Samanta","year":"2018","journal-title":"ACS Infect. Dis."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Jurado-Mart\u00edn, I., Sainz-Mej\u00edas, M., and McClean, S. (2021). Pseudomonas aeruginosa: An Audacious Pathogen with an Adaptable Arsenal of Virulence Factors. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22063128"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"e202000958","DOI":"10.26508\/lsa.202000958","article-title":"Cell-free expression of the outer membrane protein OprF of Pseudomonas aeruginosa for vaccine purposes","volume":"4","author":"Mayeux","year":"2021","journal-title":"Life Sci. Alliance"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s13054-020-2792-z","article-title":"Efficacy, immunogenicity, and safety of IC43 recombinant Pseudomonas aeruginosa vaccine in mechanically ventilated intensive care patients-a randomized clinical trial","volume":"24","author":"Adlbrecht","year":"2020","journal-title":"Crit. Care"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1128\/IAI.00850-10","article-title":"Full virulence of Pseudomonas aeruginosa requires OprF","volume":"79","author":"Chapalain","year":"2011","journal-title":"Infect. Immun."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41598-020-79678-0","article-title":"Pseudomonas aeruginosa OprF plays a role in resistance to macrophage clearance during acute infection","volume":"11","author":"Moussouni","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.jsps.2019.11.021","article-title":"Association of OprF mutant and disturbance of biofilm and pyocyanin virulence in Pseudomonas aeruginosa","volume":"28","author":"Bukhari","year":"2020","journal-title":"Saudi Pharm. J."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"39211","DOI":"10.1074\/jbc.M111.280933","article-title":"Structural basis for the interaction of lipopolysaccharide with outer membrane protein H (OprH) from Pseudomonas aeruginosa","volume":"286","author":"Edrington","year":"2011","journal-title":"J. Biol. Chem."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.bpj.2016.12.006","article-title":"Refinement of OprH-LPS Interactions by Molecular Simulations","volume":"112","author":"Lee","year":"2017","journal-title":"Biophys. J."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"5061","DOI":"10.1021\/acs.biochem.6b00630","article-title":"Molecular Interactions of Lipopolysaccharide with an Outer Membrane Protein from Pseudomonas aeruginosa Probed by Solution NMR","volume":"55","author":"Kucharska","year":"2016","journal-title":"Biochemistry"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"20747","DOI":"10.1073\/pnas.1221552110","article-title":"Enhanced in vivo fitness of carbapenem-resistant oprD mutants of Pseudomonas aeruginosa revealed through high-throughput sequencing","volume":"110","author":"Skurnik","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1128\/AAC.05451-11","article-title":"Alterations of OprD in carbapenem-intermediate and -susceptible strains of Pseudomonas aeruginosa isolated from patients with bacteremia in a Spanish multicenter study","volume":"56","author":"Cabot","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Shen, J., Pan, Y., and Fang, Y. (2015). Role of the Outer Membrane Protein OprD2 in Carbapenem-Resistance Mechanisms of Pseudomonas aeruginosa. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0139995"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s13568-021-01243-3","article-title":"Upstream region of OprD mutations in imipenem-resistant and imipenem-sensitive Pseudomonas isolates","volume":"11","author":"Kiani","year":"2021","journal-title":"AMB Express"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1093\/jac\/dkx158","article-title":"Development of carbapenem resistance in Pseudomonas aeruginosa is associated with OprD polymorphisms, particularly the amino acid substitution at codon 170","volume":"72","author":"Shu","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jcma.2017.08.016","article-title":"Investigating of four main carbapenem-resistance mechanisms in high-level carbapenem resistant Pseudomonas aeruginosa isolated from burn patients","volume":"81","author":"Rostami","year":"2018","journal-title":"J. Chin. Med. Assoc."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1016\/j.jcf.2021.03.007","article-title":"Emergence and impact of oprD mutations in Pseudomonas aeruginosa strains in cystic fibrosis","volume":"21","author":"Sherrard","year":"2022","journal-title":"J. Cyst. Fibros."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/j.1574-6968.2004.tb09639.x","article-title":"Insertional inactivation of oprD in clinical isolates of Pseudomonas aeruginosa leading to carbapenem resistance","volume":"236","author":"Wolter","year":"2004","journal-title":"FEMS Microbiol. Lett."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Huang, W., Hamouche, J.E., Wang, G., Smith, M., Yin, C., Dhand, A., Dimitrova, N., and Fallon, J.T. (2020). Integrated Genome-Wide Analysis of an Isogenic Pair of Pseudomonas aeruginosa Clinical Isolates with Differential Antimicrobial Resistance to Ceftolozane\/Tazobactam, Ceftazidime\/Avibactam, and Piperacillin\/Tazobactam. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21031026"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.3389\/fimmu.2019.01203","article-title":"Commensal Bacteria: An Emerging Player in Defense Against Respiratory Pathogens","volume":"10","author":"Khan","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/s41579-019-0288-0","article-title":"The global preclinical antibacterial pipeline","volume":"18","author":"Theuretzbacher","year":"2020","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Rezk, N., Abdelsattar, A.S., Elzoghby, D., Agwa, M.M., Abdelmoteleb, M., Aly, R.G., Fayez, M.S., Essam, K., Zaki, B.M., and El-Shibiny, A. (2022). Bacteriophage as a potential therapy to control antibiotic-resistant Pseudomonas aeruginosa infection through topical application onto a full-thickness wound in a rat model. J. Genet. Eng. Biotechnol., 20.","DOI":"10.1186\/s43141-022-00409-1"},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Fong, S.A., Drilling, A., Morales, S., Cornet, M.E., Woodworth, B.A., Fokkens, W.J., Psaltis, A.J., Vreugde, S., and Wormald, P.-J. (2017). Activity of Bacteriophages in Removing Biofilms of Pseudomonas aeruginosa Isolates from Chronic Rhinosinusitis Patients. Front. Cell Infect. Microbiol., 7.","DOI":"10.3389\/fcimb.2017.00418"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1136\/thoraxjnl-2016-209265","article-title":"Phage therapy is highly effective against chronic lung infections with Pseudomonas aeruginosa","volume":"72","author":"Waters","year":"2017","journal-title":"Thorax"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S1473-3099(18)30482-1","article-title":"Efficacy and tolerability of a cocktail of bacteriophages to treat burn wounds infected by Pseudomonas aeruginosa (PhagoBurn): A randomised, controlled, double-blind phase 1\/2 trial","volume":"19","author":"Jault","year":"2019","journal-title":"Lancet Infect. Dis."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Yang, Y., Shen, W., Zhong, Q., Chen, Q., He, X., Baker, J.L., Xiong, K., Jin, X., Wang, J., and Hu, F. (2020). Development of a Bacteriophage Cocktail to Constrain the Emergence of Phage-Resistant Pseudomonas aeruginosa. Front. Microbiol., 11.","DOI":"10.3389\/fmicb.2020.00327"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"4533","DOI":"10.1111\/1462-2920.16136","article-title":"Membrane lipid renovation in Pseudomonas aeruginosa\u2014implications for phage therapy?","volume":"24","author":"Lyon","year":"2022","journal-title":"Environ. Microbiol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1093\/jac\/dky263","article-title":"Innovations for the treatment of a complex bone and joint infection due to XDR Pseudomonas aeruginosa including local application of a selected cocktail of bacteriophages","volume":"73","author":"Ferry","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"3629","DOI":"10.1038\/s41467-023-39370-z","article-title":"Personalized aerosolised bacteriophage treatment of a chronic lung infection due to multidrug-resistant Pseudomonas aeruginosa","volume":"14","author":"Kohler","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Vaitekenas, A., Tai, A.S., Ramsay, J.P., Stick, S.M., and Kicic, A. (2021). Pseudomonas aeruginosa Resistance to Bacteriophages and Its Prevention by Strategic Therapeutic Cocktail Formulation. Antibiotics, 10.","DOI":"10.3390\/antibiotics10020145"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"909","DOI":"10.2147\/DDDT.S189847","article-title":"Mechanistic research holds promise for bacterial vaccines and phage therapies for Pseudomonas aeruginosa","volume":"13","author":"Hoggarth","year":"2019","journal-title":"Drug Des. Devel Ther."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.vaccine.2007.12.007","article-title":"Vaccines and immunotherapy against Pseudomonas aeruginosa","volume":"26","author":"Pier","year":"2008","journal-title":"Vaccine"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"170","DOI":"10.4161\/hv.26565","article-title":"A randomized, placebo-controlled phase I study assessing the safety and immunogenicity of a Pseudomonas aeruginosa hybrid outer membrane protein OprF\/I vaccine (IC43) in healthy volunteers","volume":"10","author":"Westritschnig","year":"2014","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s13054-017-1601-9","article-title":"A randomized placebo-controlled phase II study of a Pseudomonas vaccine in ventilated ICU patients","volume":"21","author":"Rello","year":"2017","journal-title":"Crit. Care"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"109","DOI":"10.15585\/mmwr.mm7104a1","article-title":"Use of 15-Valent Pneumococcal Conjugate Vaccine and 20-Valent Pneumococcal Conjugate Vaccine Among U.S. Adults: Updated Recommendations of the Advisory Committee on Immunization Practices\u2014United States, 2022","volume":"71","author":"Kobayashi","year":"2022","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Inoue, K., Kinoshita, M., Muranishi, K., Ohara, J., Sudo, K., Kawaguchi, K., Shimizu, M., Naito, Y., Moriyama, K., and Sawa, T. (2023). Effect of a Novel Trivalent Vaccine Formulation against Acute Lung Injury Caused by Pseudomonas aeruginosa. Vaccines, 11.","DOI":"10.3390\/vaccines11061088"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.4161\/21645515.2014.971641","article-title":"Anti-PcrV antibody strategies against virulent Pseudomonas aeruginosa","volume":"10","author":"Sawa","year":"2014","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"781","DOI":"10.3389\/fimmu.2019.00781","article-title":"Rational Design of a Chimeric Derivative of PcrV as a Subunit Vaccine Against Pseudomonas aeruginosa","volume":"10","author":"Wan","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1111\/1348-0421.12658","article-title":"The protective effects of nasal PcrV-CpG oligonucleotide vaccination against Pseudomonas aeruginosa pneumonia","volume":"62","author":"Naito","year":"2018","journal-title":"Microbiol. Immunol."},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Kawaguchi, K., Kinoshita, M., Sudo, K., Inoue, K., Naito, Y., Oba, M., Uchida, S., and Sawa, T. (2023). Mrna Vaccine Induces Prot. Immun. Against Type III Secret. Virulence Pseudomonas aeruginosa. biorXiv, Available online: https:\/\/www.biorxiv.org\/content\/10.1101\/2023.06.09.544431v1.","DOI":"10.1101\/2023.06.09.544431"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/s41541-023-00672-4","article-title":"Strong immune responses and protection of PcrV and OprF-I mRNA vaccine candidates against Pseudomonas aeruginosa","volume":"8","author":"Wang","year":"2023","journal-title":"NPJ Vaccines"},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Kaur, K., Reddy, S., Barathe, P., Shriram, V., Anand, U., Pro\u0107k\u00f3w, J., and Kumar, V. (2021). Combating Drug-Resistant Bacteria Using Photothermally Active Nanomaterials: A Perspective Review. Front. Microbiol., 12.","DOI":"10.3389\/fmicb.2021.747019"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"e2202794","DOI":"10.1002\/adhm.202202794","article-title":"Selective Photothermal Therapy Based on Lipopolysaccharide Aptamer Functionalized MoS(2) Nanosheet-Coated Gold Nanorods for Multidrug-Resistant Pseudomonas aeruginosa Infection","volume":"12","author":"Lv","year":"2023","journal-title":"Adv. Healthc. Mater."},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Naskar, A., and Kim, K.S. (2023). Friends against the Foe: Synergistic Photothermal and Photodynamic Therapy against Bacterial Infections. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15041116"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jconrel.2020.08.055","article-title":"Nanomaterials-based photothermal therapy and its potentials in antibacterial treatment","volume":"328","author":"Chen","year":"2020","journal-title":"J. Control Release"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"829712","DOI":"10.3389\/fphar.2022.829712","article-title":"Advances and Potentials of Polydopamine Nanosystem in Photothermal-Based Antibacterial Infection Therapies","volume":"13","author":"Fan","year":"2022","journal-title":"Front. Pharmacol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1038\/s41467-018-03473-9","article-title":"Chemo-photothermal therapy combination elicits anti-tumor immunity against advanced metastatic cancer","volume":"9","author":"Nam","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"3055","DOI":"10.1021\/acsapm.3c00204","article-title":"Molecularly Imprinted Polymers for Targeting Lipopolysaccharides and Photothermal Inactivation of Pseudomonas aeruginosa","volume":"5","author":"Zhang","year":"2023","journal-title":"ACS Appl. Polym. Mater."},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Patangia, D.V., Ryan, C.A., Dempsey, E., Ross, R.P., and Stanton, C. (2022). Impact of antibiotics on the human microbiome and consequences for host health. Microbiologyopen, 11.","DOI":"10.1002\/mbo3.1260"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.cell.2020.02.056","article-title":"The Science of Antibiotic Discovery","volume":"181","author":"Lewis","year":"2020","journal-title":"Cell"},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Grace, A., Sahu, R., Owen, D.R., and Dennis, V.A. (2022). Pseudomonas aeruginosa reference strains PAO1 and PA14: A genomic, phenotypic, and therapeutic review. Front. Microbiol., 13.","DOI":"10.3389\/fmicb.2022.1023523"},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Mart\u00ednez-Carranza, E., Garc\u00eda-Reyes, S., Gonz\u00e1lez-Valdez, A., and Sober\u00f3n-Ch\u00e1vez, G. (2020). Tracking the genome of four Pseudomonas aeruginosa isolates that have a defective Las quorum-sensing system, but are still virulent. Access Microbiol., 2.","DOI":"10.1099\/acmi.0.000132"},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Migliorini, L.B., Br\u00fcggemann, H., de Sales, R.O., Koga, P.C.M., de Souza, A.V., Martino, M.D.V., Galhardo, R.S., and Severino, P. (2019). Mutagenesis Induced by Sub-Lethal Doses of Ciprofloxacin: Genotypic and Phenotypic Differences Between the Pseudomonas aeruginosa Strain PA14 and Clinical Isolates. Front. Microbiol., 10.","DOI":"10.3389\/fmicb.2019.01553"},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"Macdonald, E., Wright, R., Connolly, J.P.R., Strahl, H., Brockhurst, M., van Houte, S., Blower, T.R., Palmer, T., and Mariano, G. (2023). The novel anti-phage system Shield co-opts an RmuC domain to mediate phage defense across Pseudomonas species. PLoS Genet., 19.","DOI":"10.1371\/journal.pgen.1010784"},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Forti, F., Roach, D.R., Cafora, M., Pasini, M.E., Horner, D.S., Fiscarelli, E.V., Rossitto, M., Cariani, L., Briani, F., and Debarbieux, L. (2018). Design of a Broad-Range Bacteriophage Cocktail That Reduces Pseudomonas aeruginosa Biofilms and Treats Acute Infections in Two Animal Models. Antimicrob. Agents Chemother., 62.","DOI":"10.1128\/AAC.02573-17"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1093\/emph\/eoy005","article-title":"Phage treatment of an aortic graft infected with Pseudomonas aeruginosa","volume":"2018","author":"Chan","year":"2018","journal-title":"Evol. Med. Public. Health"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"26717","DOI":"10.1038\/srep26717","article-title":"Phage selection restores antibiotic sensitivity in MDR Pseudomonas aeruginosa","volume":"6","author":"Chan","year":"2016","journal-title":"Sci. Rep."}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/13\/2\/119\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T13:49:07Z","timestamp":1760104147000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/13\/2\/119"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,25]]},"references-count":113,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,2]]}},"alternative-id":["antibiotics13020119"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics13020119","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,25]]}}}